At 10mg, patients have progressed through the initial titration phase and are established at one of the three recognized tirzepatide maintenance levels. MOUNJARO® 10mg KwikPen® is administered once weekly by subcutaneous injection, at any time of day, with or without food. Appropriate injection sites are the abdomen, thigh, and back of the upper arm, with the upper arm reserved for doses administered by a caregiver or clinician. Sites should be varied with each administration.

For context, the full titration schedule begins at 2.5mg once weekly for 4 weeks, then advances to 5mg. Where dose escalation continues, increases are made in 2.5mg steps no sooner than every 4 weeks, based on individual response and tolerability, up to the 15mg weekly maximum. Patients whose treatment is stable at 10mg may remain at this level as long as it remains clinically appropriate.

When a dose is missed, it may be given within the following 4 days (96 hours). After that point, the missed dose is forfeited and the next scheduled weekly dose resumes as normal. Where insulin is part of the patient’s regimen, it must be injected at a separate site — never mixed with tirzepatide in the same syringe or administered at the same location. For details on other MOUNJARO® KwikPen® doses within the titration schedule, contact the Med Supply Solutions team.

MOUNJARO® is the type 2 diabetes brand: tirzepatide in the MOUNJARO® formulation is FDA-approved as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. This on-label indication is the basis for prescribing and procuring MOUNJARO® in line with current local labeling.

Tirzepatide is also the active molecule in Zepbound®, which carries a distinct FDA indication for chronic weight management. The two brands are not interchangeable from a regulatory or indication standpoint, and licensed professionals should select the appropriate product based on the confirmed clinical context and applicable local requirements.

Three contraindications apply to MOUNJARO® regardless of dose: a personal or family history of medullary thyroid carcinoma (MTC); Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); or a documented serious hypersensitivity to tirzepatide or any excipient. Safety and efficacy in pediatric patients have been established only for those aged 10 and older with type 2 diabetes; there is no established use for patients under 18 in the weight-management setting.

MOUNJARO® 10mg KwikPen® delivers tirzepatide 10mg/0.6mL per dose. Each single-patient-use KwikPen® contains four weekly doses, providing a total of 40mg in 2.4mL (16.7mg/mL). In the U.S. prescribing information, 5mg, 10mg, and 15mg are the available weekly dose strengths after titration.

Tirzepatide is classified as a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. By engaging both receptor types, it stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon, slows gastric emptying, and reduces appetite and energy intake — a combined pharmacological action that sets it apart from GLP-1-only therapeutic agents.

The solution is clear and colorless to slightly yellow. Excipients include benzyl alcohol, glycerin, and phenol, among others detailed in the prescribing information; benzyl alcohol content is relevant in the context of the multi-dose pen format. Refrigerate at 2–8°C (36–46°F) and protect from light. If removed from refrigeration, the pen may be stored at room temperature up to 30°C (86°F) for no longer than 21 days. Do not freeze.

The SURMOUNT-1 trial reported a mean body weight reduction of approximately 21% at 72 weeks in patients receiving the 15mg tirzepatide maintenance dose. This figure pertains specifically to the 15mg dose and should not be read as applying to the 10mg maintenance dose.

Before each injection, hold the pen up and examine the solution: it should be uniformly clear and range from colorless to slightly yellow. If the liquid appears turbid, contains visible particles, or has changed color, set the pen aside and do not use it.

MOUNJARO® KwikPen® is pre-filled at a fixed dose and requires no manual setting prior to use. Attach a fresh needle immediately before each weekly injection — needles must not be reused or shared between patients. Inject subcutaneously into the abdomen, thigh, or back of the upper arm, selecting a different site each week to minimize local tissue reactions. Once the dose is delivered, remove the needle promptly and dispose of it in an approved sharps container.

Before the first dose is administered, prescribers should confirm that the patient and any involved caregiver have reviewed the manufacturer’s Instructions for Use and the product package leaflet in full.

Store the pen refrigerated at 2–8°C when not in use. Out-of-refrigerator time must not exceed 21 days, and the storage temperature must remain at or below 30°C. Protect from light. Do not freeze.